Compare TG Therapeutics Inc (TGTX) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs VNET Group Inc — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while VNET Group Inc trades at $7.52 (market cap $2.14B). The key difference: TG Therapeutics Inc is far larger — about 3.6× VNET Group Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | VNET | |
|---|---|---|
Market Cap | $7.64B | $2.14B |
Sector | Health | Technology |
52-Week High | $59.06 | $14.03 |
52-Week Low | $26.94 | $6.29 |
Enterprise Value | $7.84B | $5.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
VNET Group trades at $7.425, down 0.74% on the day, with a neutral technical signal and mixed earnings history. The stock shows a price-to-sales ratio of 1.32 and an EV/EBITDA of 26.51, but profitability remains weak with a net income margin of -21.63% and negative ROE. Recent news highlights large call option purchases and upcoming Q2 2026 earnings on August 18, 2026, amid strategic investor involvement.
The outlook is cautiously optimistic due to strong analyst buy ratings (62.5%) and AI-driven demand growth, but significant risks include persistent losses, high debt levels, and competitive pressures in China's data center market. Investors should weigh the potential from new capacity against execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
